Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Guillaume Lafrogne"'
Autor:
Bernard Vanhove, Stéphane Marot, Ray T. So, Benjamin Gaborit, Gwénaëlle Evanno, Isabelle Malet, Guillaume Lafrogne, Edwige Mevel, Carine Ciron, Pierre-Joseph Royer, Elsa Lheriteau, François Raffi, Roberto Bruzzone, Chris Ka Pun Mok, Odile Duvaux, Anne-Geneviève Marcelin, Vincent Calvez
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/9918758c1cde4a26875d41b5ad29463f
Autor:
Bernard Vanhove, Stéphane Marot, Ray T. So, Benjamin Gaborit, Gwénaëlle Evanno, Isabelle Malet, Guillaume Lafrogne, Edwige Mevel, Carine Ciron, Pierre-Joseph Royer, Elsa Lheriteau, François Raffi, Roberto Bruzzone, Chris Ka Pun Mok, Odile Duvaux, Anne-Geneviève Marcelin, Vincent Calvez
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Amino acid substitutions and deletions in the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can reduce the effectiveness of monoclonal antibodies (mAbs). In contrast, heterologous polyclonal antibodies raised
Externí odkaz:
https://doaj.org/article/6f9f8633566c421f939f2280d4799e1e
Autor:
Bernard Vanhove, Stéphane Marot, Ray T. So, Benjamin Gaborit, Gwénaëlle Evanno, Isabelle Malet, Guillaume Lafrogne, Edwige Mevel, Carine Ciron, Pierre-Joseph Royer, Elsa Lheriteau, François Raffi, Roberto Bruzzone, Chris Ka Pun Mok, Odile Duvaux, Anne-Geneviève Marcelin, Vincent Calvez
Publikováno v:
bioRxiv
Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2021, 12, pp.761250. ⟨10.3389/fimmu.2021.761250⟩
Frontiers in Immunology, 2021, 12, pp.761250. ⟨10.3389/fimmu.2021.761250⟩
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2021, 12, pp.761250. ⟨10.3389/fimmu.2021.761250⟩
Frontiers in Immunology, 2021, 12, pp.761250. ⟨10.3389/fimmu.2021.761250⟩
Frontiers in Immunology, Vol 12 (2021)
Amino acid substitutions and deletions in Spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can reduce the effectiveness of monoclonal antibodies (mAbs). In contrast, heterologous polyclonal antibodies raised
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa92c8a154f246ce4127152bd31bc37